We evaluated a quantitative solid-phase enzyme immunoassay for human choriogonadotropin 13subunit (/3-HCG) with anti-p.-HCG:horseradish peroxidase conjugate, recently marketed by Abbott Laboratories. We compared results on 56 patients' serum specimens, obtained mostly for followup of neoplastic disease, with those by a competitive radio- Human choriogonadotropin (I3-HCG) is a sialoglycoprotein hormone, normally secreted by the placenta but also produced ectopically by neoplasms (1). Immunoassays that are more sensitive than the usual pregnancy tests have been used to screen for ectopic pregnancies (2, 3), and quantitative assays have been used for diagnosis and followup of gestational trophoblastic disease (4) and germ cell neoplasma, including choriocarcinoma and testicular cancer (5). However, increased 13-HCG concentrations have also been described in serum of patients with cancer of the ovary, cervix (6), prostate (7), stomach, liver, pancreas, breast (1), and other sites. In currently used assays the antibody is directed to the /3-subunit, as described by Vaitukaitis et al. (4), but some cross reactivity is seen, especially with lutropin, in many commercial assays (8).
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Radioinununoassays have the disadvantages of waste disposal, limited shelf-life, and need for special equipment. Consequently, enzyme immunoassays have been developed in which either the antigen or antibody#{149} is labeled. Assays have been described in which f3-HCG:enzyme conjugates are used, the sensitivity of which is comparable with that of conventional RIA (9, 10). VanWeemen and Schuurs (11) developed a f3-HCG assay with antibody-enzyme conjugate, but its sensitivity was less than that of enzyme immunoassay involving f3-HCG:enzyme conjugate. Wada et al. (12) recently described an assay involving solid-phase antibody for the a-subunit and enzyme-coupled monoclonal antibody for the I3-subunit. Its sensitivity was good, but cross reactivity with lutropin was greater than with the same antibody used in competitive lilA. Abbott Laboratories recently developed a solid-phase enzyme imniunoassay with anti-13- 
Materials and Methods

Enzyme immunoassay:
With the kits we used (Abbott Laboratories Diagnostics Division,
North
Chicago, IL 60064), the procedure is briefly as follows. The standards, controls, and patients' samples are first incubated for 90 mm with anti-/3-HCG immobilized on polystyrene beads, then washed and incubated for 60 mm with anti-/3-HCG:horseradish peroxidase conjugate, and washed again to remove the excess. An o-phenylenediamine substrate and hydrogen peroxide are added and the resulting color is measured spectrophotometrically at 492 rim. The quantitative procedure in the package insert was used with duplicate specimens; standards are provided. The "Quantum II" spectrephotometer and automatic data processor used in this procedure were from Abbott. Their kit insert lists a sensitivity of si mt. unitfL and a linearity to 200 mt. unitsfL.
Comparison radioimmunoassay:
The method we used for comparison was the "/3ffl-HCG" kit (Serono Laboratories Inc., Randolph, MA 02368), a quantitative RIA in which a precipitating solution contains a second antibody and polyethylene glycol. Standards and positive and negative controls are provided in the kit. We followed the procedure recommended by Serono for "Method II" for the kit (overnight incubation).
Its sensitivity in our laboratory is sl.56 mt. units/L. In both methods the standards are calibrated against the World Health Organization Second International Standard, in which 5 mt. unitsfL is equivalent to 1 ug/L.
Patient comparison:
We analyzed, by both methods, 43 serum specimens from 40 men whose cases were being followed for testicular cancer and 13 specimens from nine women (five with gestational 
Sensitivity:
We assessed the sensitivity of the enzyme immunoassay by 20 within-assay replications of the "zero"
calibrator. The mean result plus 2 SD was considered the lower limit of detection (sensitivity).
Precision:
We used data from 24 interassay and eight intra-assay replications of Immunoassay Control Serum Level I (low) and 16 interassay and 12 intra-assay replications of Level II (intermediate) to calculate CV.
Linearity:
Three patients' specimens and a College of American Pathologists' survey specimen were serially diluted with serum diluent ("zero" calibrator) and assayed, to determine linearity.
Recovery: Known f3-HCG standards from the Serono kit, ranging from 5 to 200 mt. units/L, were diluted twofold with either Abbott's serum diluent or a patient's serum with si int. unitlL of f3-HCG. 
Results
Comparison of 23 specimens with 13-HCG results <1.56 int. units/L (by RIA) to the enzyme immunoassay method showed good correlation.
For 20 of these specimens, the enzyme immunoassay also gave results <1.56 mt. units/L, while in the other three, results were also low (2.0-2.2 mt. unitsfL). One of these three patients had evidence of disease by radiologic tests, and another did have residual embryonal carcinoma and teratoma at surgery.
Comparison With the Level H control, the mean was 18.3 mt. units/L with an interassay CV of 6.4% (SD 1.2) and an intra-assay CV of 6.5% (SD 1.2). Previous interassay precision studies with the RIA method gave a CV of 41% in the Level I control and a 9.5% CV at a higher range. Also only 3 h of incubation is required, compared with the overnight incubation for the Serono method. Finally, the longer shelf-life of enzyme immunoassay reagents and the elimination of radioactive waste disposal and gamma counters are advantageous. Overall cost per test in our laboratory would be less than for an RIA.
The enzyme immunoassay gave good results overall. Our calculated sensitivity ( 0.69 mt. unitiL) was less than the 1 mt. unitfL listed in the kit insert and for the RIA method.
Precision was better than with the RIA method, especially in the low range (CV 13% vs 40%). Patient comparison studies showed few significant clinical differences. When slight differences were found in the critical lower range (<5 int. unitafL), the enzyme immunoassay result more often correlated with the clinical impression. In the upper range, the discrepancies were not clinically important, and the large dilutions required (up to 1000-fold) tend to magnif' any differences between the methods. Recovery studies had acceptable results, and cross-reactivity studies showed low (1 to 2%) cross reactivity with lutropin and follitropin. This is similar to cross-reactivity results for the RIA, and is better than in other antibody-linked enzyme immunoassay reports (12). mt. units/L, which was obviated by adequate dilution with serum diluent. This was not a problem with all patients' samples and did not occur with survey specimens or standards. Nonspecific binding to the bead might cause some of the antibody sites to be unavailable for reaction with f3-HCG and conjugate. Altered forms and fragments of f3-HCG have been described in patients with neoplasms (13) and might theoretically cause problems with this type of assay, or other serum factors could be responsible. To correct for this problem, we would suggest diluting samples in the high range of the standard curve. The upper limit before diluting may vary among patient populations and should be determined by the individual laboratories. We would recommend dilutions, at least for values >100 mt. units/L.
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which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 113, 751-758 (1972 1-3) . The therapeutic removal of aluminum with desferrioxammne and dialysis improves these patients' wellbeing significantly (4, 5). The method of choice for monitoring concentrations of aluminum in serum for the diagnosis and treatment of these patients is atomic absorption spectrometry with use of a graphite furnace (6, 7). The lack of reference material and an assayed qualitycontrol sera to ensure the reliable determination of serum aluminum by atomic absorption spectrometry has prompted us to develop and to search for suitable sera to ifil this need. We selected without conscious bias 13 commercially sup-
